
Tempest Therapeutics, Inc. (NASDAQ:TPST – Free Report) – Analysts at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for Tempest Therapeutics in a note issued to investors on Monday, November 16th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.49) per share for the year, up from their prior forecast of ($0.83). The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Tempest Therapeutics’ Q4 2026 earnings at ($0.15) EPS, FY2027 earnings at ($0.49) EPS and FY2028 earnings at ($0.46) EPS.
Several other research analysts have also recently weighed in on TPST. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempest Therapeutics in a research note on Friday, October 9th. Wall Street Zen raised Tempest Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 24th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Reduce”.
Read Our Latest Research Report on TPST
Tempest Therapeutics Price Performance
TPST opened at $0.33 on Wednesday. The stock’s fifty day moving average is $0.66 and its 200-day moving average is $1.37. Tempest Therapeutics has a one year low of $0.30 and a one year high of $9.39.
Tempest Therapeutics (NASDAQ:TPST – Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.11.
Institutional Trading of Tempest Therapeutics
An institutional investor recently bought a new position in Tempest Therapeutics stock. Squarepoint Ops LLC purchased a new position in Tempest Therapeutics, Inc. (NASDAQ:TPST – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 30,900 shares of the company’s stock, valued at approximately $34,000. Squarepoint Ops LLC owned about 0.19% of Tempest Therapeutics as of its most recent filing with the Securities & Exchange Commission. 22.52% of the stock is owned by institutional investors and hedge funds.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company focused on developing treatments for cancer. The company’s research centers on small-molecule medicines designed to affect biological pathways involved in tumor growth and the immune response. Its lead candidate, TPST-1120, is an oral inhibitor of PPARα that has been studied for advanced liver cancer, including in combination with other cancer therapies. Tempest has also worked on additional drug candidates targeting immune-related pathways.
Featured Articles
- Five stocks we like better than Tempest Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
